Nakata Hirosuke, Sugitani Seita, Yamaji Shuhei, Otsu Satoko, Higashi Yoshihito, Ohtomo Yumiko, Inoue Gen
Department of Nephrology, Japanese Red Cross Society Wakayama Medical Center, Japan.
Intern Med. 2012;51(21):3045-9. doi: 10.2169/internalmedicine.51.7876. Epub 2012 Nov 1.
We herein report two cases of pancreatitis associated with incretin-based therapies in end-stage renal disease (ESRD) patients undergoing dialysis. A 75-year-old woman with a history of liraglutide use and a 68-year-old man with a history of vildagliptin use both presented with nausea. They showed elevated levels of pancreatic enzymes and pancreatic tail swelling on CT. Their symptoms improved after discontinuing the drugs. In the absence of any obvious secondary causes of pancreatitis, we believe that the pancreatitis observed in these cases was associated with the incretin-based therapies. Few reports have been published on the safety and efficacy of incretin-based therapies in ESRD patients, and it remains uncertain whether the changes in the pancreas observed in the present cases are characteristic of ESRD patients.
我们在此报告两例终末期肾病（ESRD）透析患者中与基于肠促胰岛素的治疗相关的胰腺炎病例。一名有使用利拉鲁肽病史的75岁女性和一名有使用维格列汀病史的68岁男性均出现恶心症状。他们的胰腺酶水平升高，CT显示胰尾肿胀。停药后症状改善。在没有任何明显的胰腺炎继发原因的情况下，我们认为这些病例中观察到的胰腺炎与基于肠促胰岛素的治疗有关。关于基于肠促胰岛素的治疗在ESRD患者中的安全性和有效性的报道很少，目前病例中观察到的胰腺变化是否是ESRD患者的特征仍不确定。
